[Therapeutic effect of a combination of bufenine and beta-escine as an oral delayed-action drug in obliterating arterial diseases of the lower limbs].
Reference is made to the clinical and instrumental results observed in 40 subjects with chronic obliterating arteriopathy of the lower limbs treated for 90 days with a projective protocol based on a per os retard combination of bufenine and beta-escine. Attention is drawn to the vasoactive and antioedemigenic activity of the combination, its good tolerance, and easy administration.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004338:Drug Combinations; D004928:Escin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D009756:Nylidrin / Q000627:therapeutic use*; D012503:Saponins / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D012503:Saponins; D004928:Escin; D009756:Nylidrin
Azione terapeutica di una associazione bufenina - beta-escina, in preparazione ritardo per os, nelle arteriopatie obliteranti degli arti inferiori.